English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Hepatitis B virus (HBV) infection is highly endemic in sub-Saharan Africa, where the lifetime risk of HBV infection is over 60% and more than 8% of the population remains chronic HBV carriers. Furthermore, this area has one of the highest HBV-related liver cancer rates in the world,1 being the most common cancer in men and third most common in women.2,3 HBV infection therefore represents a significant global threat to health in the African continent.Though most countries in sub-Saharan Africa have established HBV vaccination programs for infants through the WHO and Global Vaccine Alliance (GAVI)-sponsored Expanded Program of Immunization, HBV vaccine coverage remains incomplete.4 Furthermore, the current recommendation from World Health Organisation African division (WHO-AFRO) for birth dose HBV vaccination to prevent maternal-child transmission and early horizontal transmission of HBV has not been widely implemented.5 This is a critical issue in Africa, as more than 90% of children infected with HBV early in life progress to become chronic carriers of HBV, with the attendant risks of HBV-related liver disease, liver cancer and death.6,7Severe limitations in healthcare infrastructure, availability of diagnostics and treatment mean that currently West Africa is ill-equipped to manage the exponentially increasing burden of disease relating to the HBV epidemic. Greater knowledge of the determinants of hepatocellular carcinoma (HCC) development and cost-effective point-of-care diagnostic tests for HBV-related liver disease, and HCC are significant unmet needs in West Africa.Since 1973, HBV research has been conducted …

PROLIFICA: a story of West African clinical and research collaborations to target hepatitis B-related hepatocellular carcinoma in West Africa